Diabetic cardiomyopathy: Target immune cell from mechanism to treatment
International Immunopharmacology · 2026-10 · 186 · 117116
DOI: 10.1016/j.intimp.2026.117116 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-10. Verfasst von Jingyi Lv und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University school of Medicine, Hangzhou, China; Zhejiang Key Laboratory of Cardiovascul…. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies. Die Arbeit nennt 224 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Diabetic cardiomyopathy (DCM) is a specific cardiac complication of diabetes that occurs independently of hypertension and coronary artery disease. Beyond metabolic disturbance, chronic hyperglycemia triggers immune dysfunction, contributing to myocardial inflammation, remodeling, and contractile impairment. This review highlights the critical roles of multiple immune cell populations-including monocytes, macrophages, mast cells, neutrophils, and T lymphocytes-in the pathogenesis of DCM, and frames DCM as an immunometabolic disorder driven in part by trained immunity. Hyperglycemia enhances glycolysis in macrophages and neutrophils, leading to the accumulation of acetyl-CoA that serves as a substrate for histone acetyltransferases. The resulting hyperacetylation of histone H3 locks immune cells into a pro-inflammatory state even after glucose levels normalize and amplifies inflammasome activation via the NLRP3 pathway, thereby coupling metabolic reprogramming to epigenetic reprogramming and sustaining chronic inflammation. In parallel, hyperglycemia-induced metabolic changes promote reactive oxygen species (ROS) production and upregulate S100A8/A9 expression. The S100A8/A9 heterodimer engages the receptor for advanced glycation end products (RAGE) on myeloid progenitors, driving the expansion of monocytes/macrophages and pro-inflammatory neutrophils and further fueling adverse cardiac remodeling. We also summarize emerging immunomodulatory therapies, including anti-cytokine strategies, inhibitors of inflammatory signaling pathways, mesenchymal stromal cell (MSC)-based interventions, other cellular treatments, and nanotechnology-enabled delivery platforms, which have shown promising anti-inflammatory and cardioprotective effects in preclinical models and early clinical studies. Targeting trained immunity and immunometabolic pathways may offer novel opportunities to halt or even reverse DCM progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University school of Medicine, Hangzhou, China; Zhejiang Key Laboratory of Cardiovascular Intervention and Precision Medicine, Hangzhou, China; Engineering R…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lv, J., Bao, X., Jiao, X., Jiang, Y., Lin, M., Zhang, W., & Wang, M. (2026). Diabetic cardiomyopathy: Target immune cell from mechanism to treatment. International Immunopharmacology, 186, 117116. https://doi.org/10.1016/j.intimp.2026.117116
Vancouver
Lv J, Bao X, Jiao X, Jiang Y, Lin M, Zhang W, et al. Diabetic cardiomyopathy: Target immune cell from mechanism to treatment. International Immunopharmacology. 2026;186:117116. doi:10.1016/j.intimp.2026.117116
BibTeX
@article{Lv2026,
author = {Lv, Jingyi and Bao, Xiaoyi and Jiao, Xiaolu and Jiang, Yue and Lin, Maoning and Zhang, Wenbin and Wang, Min},
title = {Diabetic cardiomyopathy: Target immune cell from mechanism to treatment},
journal = {International Immunopharmacology},
year = {2026},
volume = {186},
pages = {117116},
doi = {10.1016/j.intimp.2026.117116}
}
EUVIMED